Updates on triple-negative breast cancer and immunotherapy

Rationale for routine use of IORT for early breast cancer and data for specific indications

Chest wall perforator flaps in breast cancer surgery: An overview

Advancing breast cancer treatment in Uganda by improving molecular testing

Somatic mutation profile of breast cancer in Uganda

ASCO 2023: Highlights and analysis

CDK4/6 inhibitors added to first line show no greater benefit when compared to their use in second line therapy in HR+, HER2- ABC

Prognostic value of HER2-low status in breast cancer: A systematic review and meta-analysis

PHERGain trial ID's early breast cancer cases that benefit from dual HER2 blockade without chemo

ASCO 2023: Breast cancer research highlights

Adding ribociclib to endocrine therapy shows an improvement in invasive disease-free survival in HR+/HER2 BC patients

Nine-weeks trastuzumab still effective compared with one year trastuzumab for early-stage HER2 positive breast cancer